GW&K Investment Management LLC Purchases 242,333 Shares of Insmed, Inc. (NASDAQ:INSM)

GW&K Investment Management LLC lifted its holdings in Insmed, Inc. (NASDAQ:INSM - Free Report) by 21.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,377,726 shares of the biopharmaceutical company's stock after purchasing an additional 242,333 shares during the quarter. Insmed accounts for about 1.0% of GW&K Investment Management LLC's investment portfolio, making the stock its 9th biggest holding. GW&K Investment Management LLC owned 0.76% of Insmed worth $105,107,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of INSM. National Bank of Canada FI increased its position in Insmed by 9.7% during the fourth quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company's stock valued at $115,000 after acquiring an additional 147 shares during the last quarter. M&T Bank Corp increased its position in Insmed by 4.7% in the first quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock worth $252,000 after buying an additional 147 shares in the last quarter. Snowden Capital Advisors LLC increased its position in Insmed by 2.5% in the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock worth $456,000 after buying an additional 158 shares in the last quarter. Cullen Frost Bankers Inc. increased its position in Insmed by 164.9% in the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 221 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. increased its position in Insmed by 3.7% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 6,314 shares of the biopharmaceutical company's stock worth $436,000 after buying an additional 225 shares in the last quarter.

Insiders Place Their Bets

In other news, CFO Sara Bonstein sold 57,766 shares of Insmed stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $89.12, for a total transaction of $5,148,105.92. Following the completion of the transaction, the chief financial officer directly owned 103,412 shares of the company's stock, valued at $9,216,077.44. The trade was a 35.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO William Lewis sold 129,805 shares of Insmed stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $100.39, for a total value of $13,031,123.95. Following the completion of the transaction, the chief executive officer owned 233,924 shares of the company's stock, valued at approximately $23,483,630.36. This represents a 35.69% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 548,197 shares of company stock valued at $49,124,834. 3.00% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

INSM has been the subject of a number of analyst reports. Jefferies Financial Group restated a "buy" rating on shares of Insmed in a research report on Tuesday, June 10th. HC Wainwright upped their price objective on Insmed from $90.00 to $120.00 and gave the stock a "buy" rating in a research note on Wednesday, June 11th. Royal Bank Of Canada upped their price objective on Insmed from $99.00 to $106.00 and gave the stock an "outperform" rating in a research note on Wednesday, June 11th. Leerink Partners upped their price objective on Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 10th. Finally, JPMorgan Chase & Co. upped their price objective on Insmed from $90.00 to $111.00 and gave the stock an "overweight" rating in a research note on Tuesday, July 8th. One investment analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, Insmed has a consensus rating of "Moderate Buy" and an average price target of $109.20.

Insmed Trading Up 0.1%

INSM stock traded up $0.14 during midday trading on Tuesday, reaching $102.92. 1,527,519 shares of the company traded hands, compared to its average volume of 2,294,768. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $106.83. The company has a debt-to-equity ratio of 11.38, a quick ratio of 5.44 and a current ratio of 5.86. The business has a 50 day moving average of $87.63 and a 200-day moving average of $78.86. The firm has a market capitalization of $19.52 billion, a price-to-earnings ratio of -17.30 and a beta of 0.90.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The business had revenue of $92.82 million during the quarter, compared to analysts' expectations of $91.63 million. Insmed had a negative return on equity of 446.98% and a negative net margin of 265.93%. The company's quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.06) earnings per share. As a group, sell-side analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.